Prices as of 2026/10/30 close
Company comparison · Mid-Tier Pharma & Drug Discovery
Kaken is the bigger company, with revenue of ¥76.9B — 2.6x Nxera's ¥29.6B.
Kaken earns more on each yen of sales, with an operating margin of -1.2% — 27.4 points above Nxera (-28.6%).
Revenue growth in the latest results: Nxera +2.7%, Kaken −18.3%.
Nxera pays more on average — ¥12.6M against ¥8.75M at Kaken.
Over the past year the shares moved Nxera +58.2%, Kaken +5.2%.
Head-to-head wins13 metrics
One win per metric for the company with the best value. Metrics with no better or worse (P/E, average age, employees) are excluded.
ScaleInvestors
Kaken aheadKaken 3 : Nxera 0
Revenue: Kaken ¥76.9B / Nxera ¥29.6B
ProfitabilityInvestors
Kaken aheadKaken 3 : Nxera 1
Operating margin: Kaken −1.2% / Nxera −28.6%
GrowthInvestors
Nxera aheadKaken 0 : Nxera 1
Revenue growth (YoY): Kaken −18.3% / Nxera +2.7%
Stock & balance sheetInvestors
Nxera aheadKaken 1 : Nxera 2
Share price, 1 year: Kaken +5.2% / Nxera +58.2%
Pay & workforceJob seekers
EvenKaken 1 : Nxera 1
Average salary: Kaken ¥8.75M / Nxera ¥12.6M
| Metric | Kaken | Nxera | Gap |
|---|---|---|---|
| Revenue | ◎¥76.9B | ¥29.6B | 2.6x |
| Operating profit | ◎−¥899M | −¥8.5B | |
| Net income | ◎¥2.1B | −¥12.5B |
| Metric | Kaken | Nxera | Gap |
|---|---|---|---|
| Operating margin | ◎−1.2% | −28.6% | 27.4pt |
| Net margin | ◎2.8% | −42.3% | 45.1pt |
| ROE | ◎1.4% | −19.3% | 20.7pt |
| Revenue per employee | ¥71M | ◎¥592M | 8.4x |
| Metric | Kaken | Nxera | Gap |
|---|---|---|---|
| Revenue growth (YoY) | −18.3% | ◎+2.7% | 21.0pt |
| Guidance: revenue growthnext FY plan | +16.9% | — |
| Metric | Kaken | Nxera | Gap |
|---|---|---|---|
| Share price, 1 year | +5.2% | ◎+58.2% | 53.0pt |
| Share price, 3 months | −2.0% | ◎+68.6% | 70.7pt |
| P/E (trailing)lower = cheaper | 67.7x | — | |
| Equity ratio | ◎82.8% | 45.3% | 37.6pt |
| Share price (close) | ¥3,830 | ¥1,440 |
◎ marks the best value for each metric. Revenue and profit are from the latest full-year earnings release; share prices are closing-price references; P/E = latest close ÷ trailing EPS. For banks and some other financials, revenue means ordinary income.
| Metric | Kaken | Nxera | Gap |
|---|---|---|---|
| Average salary | ¥8.75M | ◎¥12.6M | ¥3.82M |
| Starting salary (monthly) | ¥268,100 | — | |
| Average tenure | ◎17.3 yrs | 3.7 yrs | 13.6 |
| Average age | 41.9 | 46.8 | 4.9 |
| Employees | 1,086 | 50 | 21.7x |
Average salary is for the reporting (parent) company and is affected by average age and job mix. Holding companies with few employees are left out of the salary comparison.
Close (Oct 30, 2026)
¥3,830+5.2% (1Y)
Kaken +5.2% over 1Y. Compared: Nxera +58.2%.
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Each line shows the % change from the start of the period. Updated Oct 30, 2026.
Kaken2 segments
Nxera1 segments
AAverage annual salary from the securities filings: Nxera ¥12.6M, Kaken ¥8.75M. Nxera pays the most. Averages also depend on staff age and job mix, so check the average age too (Kaken 41.9, Nxera 46.8).
ARevenue in the latest results: Kaken ¥76.9B, Nxera ¥29.6B. Kaken is the bigger company, with revenue of ¥76.9B — 2.6x Nxera's ¥29.6B.
AOperating margins: Kaken -1.2%, Nxera -28.6%. Kaken turns the highest share of sales into operating profit.
AShare price change over the past year (closing prices, for reference): Nxera +58.2%, Kaken +5.2%. Nxera has risen the most.
Comparing 2 companies (up to 4)
Sources: earnings releases (kessan tanshin), annual securities reports and other public information. Share prices are closing-price references, not real-time. Our data may contain errors; investment decisions are your own responsibility.
